INCATE supports innovators
to fight drug-resistant bacterial infections
Our Mission
Supporting innovators to fight drug-resistant infections
INCATE brings together translational and basic research, industry, experienced entrepreneurs and investors from across Europe to accelerate your innovation. We do this by providing advice, community and funding. Our focus is on the development of new therapies, and interventions that help reduce the prevalence and impact of Antimicrobial Resistance (AMR).
Whats up?
Latest News
The INCATE Team is happy to share some exciting news: the INCATE Selection Committee has awarded Stage II support to Brigid Bio, a University of Aberdeen spin-out. This award recognizes Brigid Bio’s groundbreaking work in [...]
Over the past four years, INCATE has been supporting early-stage ventures working on innovations to [...]
Unison Medicines is delighted to announce an oversubscribed first close of $500k of financing from [...]
We are happy to announce a new partnership with Granzer Regulatory Consulting & Services GmbH [...]
From bone flutes to synths, music has always been more than noise — it’s how [...]
What we do
Supporting your venture
Advice
Advice from partners, including Industry, to enable; early alignment with medical needs and market demand, the development of a quality translational path and a plan to build a company.
Community
Access to a community of engaged individuals across industry, academia, entrepreneurs, policymakers, investors, public health and healthcare providers to share ideas and fight drug-resistant bacterial infections together.
Funding
Up to €250,000 in non-dilutive funding will be provided to selected projects to help answer critical questions needed to develop business and translational plans to convince investors at the next funding stage.
